An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers.
1 de diciembre de 2015 actualizado por: Theresa Winhusen, University of Cincinnati
An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association With Treatment Outcomes in Methamphetamine and Cocaine Abusers
The purpose of this study is to determine whether performance on neurocognitive measures predicts treatment outcomes in individuals with substance abuse disorders.
A second purpose is to compare the risk of damage, as well as actual damage, to DNA and other cell parts in people with substance abuse disorders to that of people who do not have substance abuse disorders.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
The primary objective of this study is to replicate the finding that performance on the Stroop color-word interference task is predictive of treatment completion in participants with cocaine use disorders and to extend this finding to participants with Methamphetamine use disorders. Secondary objectives include evaluating whether:
- performance on various neurocognitive measures, including the Stroop, Rey Auditory-Verbal Learning Test (RAVLT), Iowa Gambling Task (GT), Wisconsin Card Sorting Task (WCST), the Barratt Impulsiveness Scale version -11 (BIS-11), and the Frontal Systems Behavior Scale (FrSBe) is predictive of treatment attrition and stimulant use outcomes in METH/cocaine abusers;
- neurocognitive test performance is associated with oxidative damage, a severe consequence of oxidative stress, in METH/cocaine abusers;
- oxidative damage is predictive of treatment attrition and substance use outcomes in METH/cocaine abusers,
- oxidative damage in METH/cocaine abusers is significantly greater than that of a normal comparison group and
- exploratory analyses reveal a significant relationship among oxidative stress, neurocognitive function, and treatment outcomes in METH/cocaine abusers.
Tipo de estudio
De observación
Inscripción (Actual)
217
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32211
- Gateway Community Services
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43207
- Maryhaven
-
-
Oregon
-
'Eugene, Oregon, Estados Unidos, 97402
- Willamette Family Treatment Services
-
Portland, Oregon, Estados Unidos, 97292
- ChangePoint, Inc.
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75228
- Nexus Recovery Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98122
- Recovery Centers of King County
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 99 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
Persons randomized into the National Drug Abuse Treatment Clinical Trials Network STAGE-12 Study (CTN-0031- NCT00573183)
Descripción
Inclusion Criteria (METH and/or Cocaine Dependent Group):
- be randomized into the CTN-0031 (STAGE-12) trial
- current abuse or dependence for METH and/or cocaine
- endorse METH and/or cocaine as the primary drug of choice
- able to correctly distinguish the colored stimuli on the Stoop task.
Exclusion Criteria (METH and/or Cocaine Dependent Group):
- history of stroke
- history of a seizure disorder
Inclusion Criteria (Non-METH and/or Cocaine Dependent Group):
- be 18 years of age or older
- be able to understand the study and provide written informed consent in English
Exclusion Criteria (Non-METH and/or Cocaine Dependent Group):
- history of stroke
- history of a seizure disorder
- positive urine toxicology screen
- screen positive for Major Depressive Syndrome, other Depressive Syndrome, Panic Syndrome, or other Anxiety Syndrome
- meet criteria for ADHD
- have HIV/AIDS
- history of an injury in which consciousness was lost for more than 30 minutes
- meet DSM-IV criteria for dependence (either current or lifetime) for any psychoactive substance other than nicotine or for abuse (both current and lifetime) for any psychoactive substance other than nicotine or for alcohol for which a life-time history of abuse is allowed
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Control de caso
- Perspectivas temporales: Transversal
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
METH and/or cocaine dependent group
The METH and/or cocaine dependent group were also enrolled in CTN0031 (NCT00573183) and seeking treatment.
This group will be analyzed based on whether or not they completed treatment as defined by the study.
|
|
Non METH and/or cocaine dependent group
The Non METH and/or cocaine dependent group participants are normal controls recruited from the community.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Stroop Color-word Task
Periodo de tiempo: Single study visit
|
The primary objective of this study was to replicate the finding that performance on the Stroop color-word interference task is predictive of treatment completion in participants with cocaine use disorders (Streeter et al., 2007) and to extend this finding to participants with methamphetamine use disorders.
In the Stroop, the participant is required to name the color of the ink in which a word is printed while inhibiting the overlearned response of reading the word (e.g., the word ''red'' might be printed in blue ink).
The number of errors were subtracted from the time required (RT; Reaction Time) for each of the 3 trials, yielding three summary scores.
The derived interference score is obtained by subtracting the RT for the first trial from the RT for the third trial.
|
Single study visit
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Barrett Impulsiveness Scale Version 11 (BIS-11)
Periodo de tiempo: Single study visit
|
The BIS-11 consists of 30 self-report items, with responses in a four-point Likert-type scale (0 - 3)ranging from "Rarely/Never" to "Almost Always/Always" and comprises three domains: Attentional impulsiveness (AI), Motor impulsiveness (MI), and Non-planning impulsiveness (NP); these three domains are summed to yield a total score; higher scores reflect greater impulsivity.
The total score was utilized as the BIS-11 predictor measure (possible score range 0 - 90).
|
Single study visit
|
|
Tail Length From the Comet Assay for Oxidative Damage
Periodo de tiempo: Single study visit
|
The test for oxidative damage was derived from a blood sample which was analyzed for tail length from the comet assay; higher scores reflect greater oxidative damage.
|
Single study visit
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Theresa Winhusen, Ph.D., University of Cincinnati
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Winhusen TM, Somoza EC, Lewis DF, Kropp FB, Horigian VE, Adinoff B. Frontal systems deficits in stimulant-dependent patients: evidence of pre-illness dysfunction and relationship to treatment response. Drug Alcohol Depend. 2013 Jan 1;127(1-3):94-100. doi: 10.1016/j.drugalcdep.2012.06.017. Epub 2012 Jul 6.
- Winhusen T, Walker J, Brigham G, Lewis D, Somoza E, Theobald J, Somoza V. Preliminary evaluation of a model of stimulant use, oxidative damage and executive dysfunction. Am J Drug Alcohol Abuse. 2013 Jul;39(4):227-34. doi: 10.3109/00952990.2013.798663. Epub 2013 Jun 28.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de febrero de 2008
Finalización primaria (Actual)
1 de octubre de 2009
Finalización del estudio (Actual)
1 de marzo de 2010
Fechas de registro del estudio
Enviado por primera vez
3 de marzo de 2008
Primero enviado que cumplió con los criterios de control de calidad
3 de marzo de 2008
Publicado por primera vez (Estimar)
5 de marzo de 2008
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
30 de diciembre de 2015
Última actualización enviada que cumplió con los criterios de control de calidad
1 de diciembre de 2015
Última verificación
1 de diciembre de 2015
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- NIDA-CTN-0031A
- U10DA013732 (Subvención/contrato del NIH de EE. UU.)
- 5U10DA013732 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .